We are live on ! Find out more

Unicycive Therapeutics

UNCY

Market cap $106M

3.81 USD

+0.05

1.33%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

3.83

+0.02

0.52%

1 day

1.33%

5 days

-3.54%

1 month

-16.26%

3 months

-19.62%

6 months

-46.79%

Year to date

-34.31%

1 year

-20.62%

5 years

-86.82%

10 years

-93.49%

About: Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.

Employees: 22

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 99.5%

Negative 0.5%

Kaplan Fox Alerts Investors: Lead Plaintiff Deadline for Unicycive Therapeutics, Inc. (UNCY) is November 2, 2026

New York, New York--(Newsfile Corp. - October 29, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) on behalf of investors that purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Unicycive and have suffered losses, you may CLICK HERE to contact us.

Kaplan Fox Alerts Investors: Lead Plaintiff Deadline for Unicycive Therapeutics, Inc. (UNCY) is November 2, 2026

UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics Securities Lawsuit - Contact SueWallSt

A securities class action contends Unicycive Therapeutics promised shareholders an FDA decision on June 29, 2026 and a commercial launch of oxylanthanum carbonate "later this year," while allegedly never inspecting the third-party manufacturing facility that had already triggered one Complete Response Letter. NEW YORK, Oct. 29, 2026 /PRNewswire/ -- SueWallSt notifies investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) that a class action has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026.

UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics Securities Lawsuit - Contact SueWallSt

Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Unicycive (UNCY) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/2/2026

Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

DEADLINE ALERT for Hims & Hers Health, Inc. (HIMS), Unicycive Therapeutics, Inc. (UNCY), Papa John's International, Inc. (PZZA), and FuelCell Energy, Inc. (FCEL): The Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Lead plaintiff deadlines are approaching in securities class actions filed on behalf of investors in Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., Papa John's International, Inc., and FuelCell Energy, Inc. Lead plaintiff deadlines are approaching in securities class actions filed on behalf of investors in Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., Papa John's International, Inc., and FuelCell Energy, Inc.

DEADLINE ALERT for Hims & Hers Health, Inc. (HIMS), Unicycive Therapeutics, Inc. (UNCY), Papa John's International, Inc. (PZZA), and FuelCell Energy, Inc. (FCEL): The Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky

A securities class action names Unicycive Therapeutics' Chief Executive Officer and Chief Financial Officer as individual defendants under Section 20(a) control person claims, alleging they controlled disclosures telling shareholders a third-party manufacturer had made "significant progress" toward FDA compliance that the Company had never verified through its own inspection. NEW YORK, Oct. 28, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) that a securities class action naming Chief Executive Officer Shalabh Gupta and Chief Financial Officer John Townsend as individual defendants has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026.

UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky

UNCY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 28, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

UNCY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

UNCY DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCY

New York, New York--(Newsfile Corp. - October 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline. SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

UNCY DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCY

UNCY Deadline: Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026. Unicycive describes itself as a “clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases.”For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767.

UNCY Deadline: Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders to Contact the Firm for Information About Their Rights

UNCY URGENT DEADLINE: Unicycive Therapeutics, Inc. Investors Have Until November 2nd to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff Role

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options

UNCY URGENT DEADLINE: Unicycive Therapeutics, Inc. Investors Have Until November 2nd to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff Role

DEADLINE ALERT for York Space Systems, Inc. (YSS), Hims & Hers Health, Inc. (HIMS), Unicycive Therapeutics, Inc. (UNCY), and Papa John's International, Inc. (PZZA): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions

Investors in York Space Systems, Inc., Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., and Papa John's International, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions Investors in York Space Systems, Inc., Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., and Papa John's International, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions

DEADLINE ALERT for York Space Systems, Inc. (YSS), Hims & Hers Health, Inc. (HIMS), Unicycive Therapeutics, Inc. (UNCY), and Papa John's International, Inc. (PZZA): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions

See News Rankings

Price charts implemented using Lightweight Charts™